Section Three Blood Toxicology

3.6 Qualitative Liquid-Liquid Extraction Methods for GC/MSD Confirmation 3.6.1 Liquid-Liquid Extraction Procedure for the Recovery of Neutral and Basic Drugs from Blood

3.6.1.1 BACKGROUND

This method is a general blood extraction procedure for a variety of commonly encountered neutral and basic drugs along with their metabolites. This method prepares an extract which will be subjected to confirmatory analysis with a gas chromatograph with a mass selective detector (GC\MSD). This method does not efficiently extract some basic compounds, such as morphine and hydromorphone, due to pKa/pH considerations.

3.6.1.2 SCOPE

The method is based upon the principle of liquid/liquid extraction. Positive controls are spiked for a resulting concentration of 200ng/mL or 500ng/mL of drugs of interest. The sample of is a drusted with a pH 9.2 borate buffer and extracted with n-butyl extoride. An optional back extraction procedure removes most frequently encountered interfering substances. Two internal standards are used to monitor extraction efficiency and chromatographic performance. Gas chromatography in conjunction with full scan mass spectrometry is used to confirm the presence of basic and neutral analytes of interest. The method allows for the analyst to use either methanol or ethyl acetate as a reconstitution solvent. Some benzodiazepines are more efficiently extracted using ethyl acetate than methanol as a reconstitution solvent. In addition, samples reconstituted in ethyl acetate can also be derivatized to increase sensitivity and detection of some compounds. Some drugs are more efficiently extracted using methanol as a reconstitution solvent. It is at the analyst's discretion to determine which solvent to use.

3.6.1.3 EQUIPMENT AND SUPPLIES

3.6.1.3.1	Tube Rocker
3.6.1.3.2	Vortex Mixer
3.6.1.3.3	Evaporative concentrator equipped with nitrogen tank.
3.6.1.3.4	16 x 100mm round bottom glass screw-top tubes
3.6.1.3.5	Screw Cap for 16mm O.D. tubes
3.6.1.3.6	GC/MS Automated Liquid Sampler (ALS) vials
3.6.1.3.7	GC/MS vial microinsert
3.6.1.3.8	Gas Chromatograph equipped with a Mass Selective Detector
3.6.1.3.9	5%-Diphenyl-95%-Dimethyl-siloxane copolymer capillary
	GC column, 12.5 to 30M.

3.6.1.4 **REAGENTS**

Refer to Manual section 5.12 for solution preparation instructions.

- 3.6.1.4.1 Methanol (ACS Grade)
- 3.6.1.4.2 n-Butyl chloride (ACS Grade)
- 3.6.1.4.3 Borate Buffer (pH 9.2)
- 3.6.1.4.4 Deionized/Distilled (DI) Water
- 3.6.1.4.5 1% Hydrochloric Acid in Methanol
- 3.6.1.4.6 100mM Hydrochloric Acid
- Ethyl Acetate (ACS Grade) 3.6.1.4.7
- BFTSA or MFTSA with 1% TMCS 3.6.1.4.8

REFERENCE MATERIAL 3.6.1.5

3.6.1.5.1 Positive Control

Positive Control can be prepared with the working solution described below and/or obtained commercially.

	pelow and/or obtained commerce	
3.6.1.5.1.1	Positive Control Stock Sol	
	Obtain 1mg/mL stock drug	
	through Cerilliant, Alltech	
	appropriate vendor.	
3.6.1.5	Positive Control Working	
CX'O	Add the designated volum	
2	to T0mL methanol. A	minimum of four
\sim	compounds must be used.	
(10, 60, 1	Solution is stable for 6-mor	
	room temperature or 12-m	
	under refrigeration. Re-m	ake solution when
	deterioration is noted.	
perty asoli	deterioration is noted.	
a coperty of SOL	Stock Solution (1.0mg/mL)	Volume
Property OBSOL	Stock Solution (1.0mg/mL)	
Property OBSOL	Stock Solution (1.0mg/mL) Amitriptyline	Volume
Property OBSOL	Stock Solution (1.0mg/mL) Amitriptyline	Volume (µL)
3.6.1.5 Kg State OBSOLL OBS	Stock Solution (1.0mg/mL) Amitriptyline Caffeine	Volume (µL)
property obsolv	Stock Solution (1.0mg/mL) Amitriptyline Caffeine Codeine	Volume (µL)
property obsolv	Codeine	Volume (μL) 20 20
Property OBSOL	Codeine Diphenhydramine	Volume (μL) 20 20 20 20
property obsolv	Codeine	Volume (μL) 20 20 20
Property OBSOL	Codeine Diphenhydramine	Volume (μL) 20 20 20 20

Methadone	20
Nicotine	20
PCP	20
Trazodone	50
Methamphetamine	20

3.6.1.5.2 <u>Internal Standard</u>

3.6.1.5.2.1 Stock Solutions

1 mg/mL Benzphetamine 1 mg/mL Papaverine

3.6.1.5.2.2 Working Internal Standard Solution [10ng/μL]

Add 100µL Benzphelamine and Papaverine stock solutions to 10nL volumetric ball flask. QS with methanol.

Solution is stable for three months when stored at room temperature.

3.6.1.5.3 <u>Negative Control</u>

Negative Whole Blood

3.6.1.5.4 Reference Standards

Stock Standard Solution

Obtain 1mg/mL stock drug standard solutions through Cerilliant, Alltech, Sigma or other appropriate vendor.

Working Drug Standard Solution

Add the designated volume of stock solution to 10mL methanol.

3.6.1.6 PROCEDURE

3.6.1.6.1 Initial set-up

For each control and case sample label two sets of screw-top extraction tubes and one ALS vial with microinserts.

3.6.1.6.2 <u>Positive Control Samples</u>

Use the same lot of negative blood used to prepare the negative control to prepare positive controls.

3.6.1.6.2.1 Prepare a control sample by adding 200μL mixed working control solution to 2mL

Page 3 of 8

Rev. 5 Issued: 10/29/2012 BLOOD 3.6.1- Basic-Neutral Issuing Authority: Quality Manager negative whole blood or pipette a 2mL sample of commercially obtained whole blood positive control.

- 3.6.1.6.2.2 When the optional back extraction is used, prepare an additional positive control to parallel the back extraction process.
- 3.6.1.6.2.3 When some samples in a batch are going to be reconstituted with methanol and others with ethyl acetate, a separate positive control must be run for each reconstitution solvent.

3.6.1.6.3 <u>Casework Samples</u>

Transfer 2mL casework sample to screw top extraction tube.

3.6.1.6.4 Negative Control Sample

Transfer 2mL negative whole blood to extraction tube. If some samples are going to be run with ethyl acetate and some with methanol as a reconstitution solvent, a negative control must be prepared and run for each reconstitution solvent.

3.6.1.6.5 Internal Standard

3.6.1.6.5.1 Add 20µN of internal standard mixture.

Wortex. If benzodiazepines are of interest, it is also recommended that 3μL of Prazepam (1 mg/mL) be spiked into the sample as well.

Allow sample to stand 10 minutes.

Initial Extraction

3.6.1.6.6.1 Add 2mL borate buffer. Vortex.

3.6.1.6.6.2 Pipet 4mL n-butyl chloride into each tube, cap.

3.6.1.6.6.3 Place tube on rocker for 10 minutes.

3.6.1.6.6.4 Centrifuge for 10 minutes at 3400 rpm.

3.6.1.6.6.5 Transfer the n-butyl chloride layer (upper) to second screw-top tube.

3.6.1.6.6.6 Add 50uL 1% HCl in methanol.

	3.6.1.6.6.7	Evaporate to dryness under N_2 at $\leq 37^{\circ}$ C.
	no clean-up	proceed to 3.6.1.6.8.
3.6.1.6.7	Optional Sam	ple Clean-up
	3.6.1.6.7.1	Reconstitute with 50ul 100mM HCl.
	3.6.1.6.7.2	Add 1ml of n-Butyl Chloride. Vortex.
	3.6.1.6.7.3	Rock for 5 minutes.
	3.6.1.6.7.4	Centrifuge for 5 minutes at 3400 rpm.
	3.6.1.6.7.5	Discard upper n-Butyl Charide layer.
	3.6.1.6.7.6	Add 2ml of pH 9.2 torate solution. Vortex
	3.6.1.6.7.7	Add 4 ml of Butyl Chloride.
	3.6.1.6.7.8	Rock for 5 minutes.
	3.6.1.6.7.9	Centrifuge for 5 minutes at 3400 rpm.
	3.6.1.6.7.10	Transfer upper n-Butyl Chloride layer into sciew-top/tube.
		0 1/1/2
<u> </u>	3,6.1.6.7.1	Evaporate to just dryness under N_2 at ≤ 45 °C.
3.6.1.6.8	Reconstitution	
of lov	3.61.6.84	Add 50uL Methanol or Ethyl Acetate to the residue, vortex.
erty C	3.6 1.6.8.2	Transfer extract to labeled ALS vial with microinsert.
3.6.1.6.	Preparation for 3.6.1.6.9.1	or Analysis Run
	3.0.1.0.9.1	Into Sequence log table, enter the sample case numbers, blanks and controls.
	3.6.1.6.9.2	Load samples, standards, blank and controls into the quadrant rack as noted in the sequence table.
3.6.1.6.10	-	ivatization (at the analyst's discretion, samples eted with ethyl acetate may be derivatized)
	3.6.1.6.10.1	After ethyl acetate extraction samples have run on the GC-MSD, add 20uL BFTSA or

MFTSA to the sample. In addition to the
case samples, the extracted positive and
negative controls must also be derivatized
and run.

- 3.6.1.6.10.2 Place the samples in an oven at about 75 degrees Celsius for approximately 15 minutes.
- 3.6.1.6.10.3 Allow samples to cool and run on GC-MSD

3.6.1.6.11 GC-MSD Analysis Parameters

- 3.6.1.6.11.1 Refer to instrument METHOD printout for current analysis parameters.
- 3.6.1.6.11.2 Current analysis the thod must be stored centrally as a hard or electronic copy.

3.6.1.6.12 GC-MSD Qualitative Detection and Identification Criteria

3.6.1.6.12.1 For the identification of compounds not included in positive control, analyze appropriate non-extracted reference standards.

3.6.1.6 12.2

The presence of a drug compound is indicated if the retention time for the sample versus applicable standard does not differ by more than ±0.2 minutes and there are no significant differences in the mass spectral data.

3.6.1.7 QUALITY ASSURANCE REQUIREMENTS

3.6.1.7.1 <u>General</u>

- 6.1.7.1.1 Blood samples are to be stored under refrigeration after aliquots are removed for analysis.
- 3.6.1.7.1.2 Refer to toxicology manual section 5.2 for balance calibration and intermediate check requirements.
- 3.6.1.7.1.3 Refer to toxicology manual section 5.8 for additional GC-MSD quality assurance requirements.

3.6.1.7.1.4 Refer to toxicology manual section 5.10 for reference material authentication requirements.

3.6.1.8 ANALYSIS DOCUMENTATION

- 3.6.1.8.1 A packet containing original data for controls will be prepared for each analysis run and stored centrally in the laboratory where the analysis was performed until archiving.
- 3.6.1.8.2 A copy of controls need not be included in individual case files. When necessary, a copy of control printouts can be prepared from the centrally stored document.

3.6.1.9 REFERENCES

- 3.6.1.9.1 Procedure for Basic Drug Analysis, Courtesy of Jim Hutchison, Montana Department of Justice, Forensic Services Division, 2005
- 3.6.1.9.2 Procedure for Back Extraction, Courtesy of Jim Hutchison, Montana Department of Justice, Forensic Services Division, 2006.
- 3.6.1.9.3 Strong Bases Extractions Screening SOP, Courtesy of Dr. Graham Jones, Office of the Chief Medical Examiner, Edmonton Carada, 2003.
- Jones, G., Postmortem Toxicology. pp. 98-102, in: Clarke's Analysis of Drugs and Poisons, 3rd Edition, Moffat, A.C., Osselton, M.D. and Widdop, B., eds., Pharmaceutical Press, 2004.
 - 6.1.9.5 Hearn, W.L. and Walls, H.C., Strategies for Postmortem Toxicology Investigation. pp. 937-939. *in:* Drug Abuse Handbook, S.B. Karch, ed., CRC Press, Boca Raton, FL, 1998.

Issued: 10/29/2012 BLOOD 3.6.1- Basic-Neutral Issuing Authority: Quality Manager

Rev. 5

Revision History

Section Three

Blood Toxicology

Qualitative Liquid-Liquid Extraction Methods for GC/MSD Confirmation
 3.6.1 Liquid-Liquid Extraction Procedure for the Recovery of Neutral and Basic Drugs from Blood.

Revision #	Issue Date	History/Comments
1	04-25-2002	Original Issue in SOP format
2	05-27-2003	Updated, Clarifications
3	11-21-2006	Addition of internal standard, extraction process restructured.
4	07-28-2008	Clarified that negative blood used to prepare positive control is the same (of as used for negative control.
5	10-29-2012	Removed requirement to run positive control in duplicate. Added option to reconstitute in ethyl acetate and derivatize
operti	y of Idaho	3 116 0
DI	O,	